Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus

키워드

참고문헌 (107)

1. Sekiba K, "Hepatitis B virus pathogenesis : fresh insights into hepatitis B virus RNA", World J Gastroenterol, 24, pp.2261~2268 (2018)
2. Wieland S, "Genomic analysis of the host response to hepatitis B virus infection", Proc Natl Acad Sci U S A, 101, pp.6659~6674 (2004)
3. Yan H, "Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus", Elife, 1, pp.e00049~ (2012)
4. Huang HC, "Entry of hepatitis B virus into immortalized human primary hepatocytes by clathrin-dependent endocytosis", J virol, 86, pp.9443~9453 (2012)
5. Macovei A, "Hepatitis B virus requires intact caveolin-1 function for productive infection in HepaRG cells", J virol, 84, pp.243~253 (2010)
6. Elkin SR, "Endocytic pathways and endosomal trafficking : a primer", Wien Med Wochenschr, 166, pp.196~204 (2016)
7. Hayes CN, "Early events in hepatitis B virus infection : from the cell surface to the nucleus", J Gastroenterol Hepatol, 31, pp.302~309 (2016)
8. Block TM, "Molecular virology of hepatitis B virus for clinicians", Clin Liver Dis, 11, pp.685~706 (2007)[DOI]
9. Diab A, "The diverse functions of the hepatitis B core", capsid protein(HBc)in the viral life cycle : implications for the development of HBc-targeting antivirals, 2018, pp.149, 211~220
10. Klumpp K, "Capsid proteins of enveloped viruses as antiviral drug targets", Curr Opin Virol, 5, pp.63~71 (2014)
11. Beck J, "Hepatitis B virus replication", World J Gastroenterol, 13, pp.48~64 (2007)
12. European Association for the Study of the Liver, "EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection", J Hepatol, 67, pp.370~398 (2017)
13. Korean Association for the Study of the Liver (KASL), "KASL clinical practice guidelines for management of chronic hepatitis B", Clinical and Molecular Hepatology, 25(2), pp.93~159 (2019), 대한간학회
14. Terrault NA, "Update on prevention, diagnosis, and treatment of chronic hepatitis B : AASLD 2018 hepatitis B guidance", Hepatology, 67, pp.1560~1599 (2018)
15. Chang TT, "A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B", N Engl J Med, 354, pp.1001~1010 (2006)
16. Marcellin P, "Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B", N Engl J Med, 359, pp.2442~2455 (2008)
17. Chang TT, "Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B", Hepatology, 51, pp.422~430 (2010)
18. Buti M, "Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection", Dig Dis Sci, 60, pp.1457~1464 (2015)
19. Werle-Lapostolle B, "Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy", Gastroenterology, 126, pp.1750~1758 (2004)
20. Lucifora J, "Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA", Science, 343, pp.1221~1228 (2014)
21. Luo X, "Clinical analysis of polyethylene glycol interferon-α treatment in 155 hepatitis B e antigen(HBeAg)-positive chronic hepatitis B(CHB)patients", Ann Hepatol, 16, pp.888~892 (2018)
22. Chan HLY, "Treatment of patients with chronic hepatitis B who have failed previous antiviral treatment with pegylated interferon alpha2a(40kda; PEGASYS)", Antivir Ther, 13, pp.555~562 (2008)
23. Yang JF, "Comparison of adverse effects related to pegylated interferon-based therapy for patients with chronic hepatitis B and chronic hepatitis C in Taiwan", Hepatol Int, 4, pp.732~740 (2010)
24. Hosaka T, "Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection", Hepatology, 58, pp.98~107 (2013)
25. Lok ASF, "Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma?", J Gastroenterol Hepatol, 26, pp.221~227 (2011)
26. Coffin CS, "The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy", Aliment Pharmacol Ther, 40, pp.1262~1269 (2014)
27. Kim MA, "Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance : a nationwide multicentre study", Gut, 69, pp.2214~2222 (2020)
28. Baecker A, "Worldwide incident hepatocellular carcinoma cases attributable to major risk factors", Eur J Cancer Prev, 27, pp.205~ (2018)
29. Schulze A, "Fine mapping of pre-s sequence requirements for hepatitis B virus large envelope proteinmediated receptor interaction", J Virol, 84, pp.1989~2000 (2010)
30. Heiner Wedemeyer, "GS-13-Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in cwith PEG-interferon Alpha 2a in patients with chronic HBV", HDV co-infection, 2019, pp.70(1), e81~[DOI]
31. Lucifora J, "Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes", Antiviral Res, 97, pp.195~197 (2013)
32. Watashi K, "Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide(NTCP)", Hepatology, 59, pp.1726~1737 (2014)
33. Armas D, "FRI-171-A phase 1 single ascending dose study of the safety, tolerability and pharmacokinetics of CRV431", J Hepatol, 70, pp.e464~e465 (2019)
34. Li D, "A potent human neutralizing antibody Fc-dependently reduces established HBV infections", Elife, 6, pp.e26738~ (2017)
35. Zhang TY, "Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen", Gut, 65, pp.658~671 (2016)
36. Neumann AU, "Novel mechanism of antibodies to hepatitis B virus in blocking viral particle release from cells", Hepatology, 52, pp.875~885 (2010)
37. Galun E, "Clinical evaluation(phase I)of a combination of two human monoclonal antibodies to HBV : safety and antiviral properties", Hepatology, 35, pp.673~679 (2002)
38. Cole AG, "Modulators of HBV capsid assembly as an approach to treating hepatitis B virus infection", Curr Opin Pharmacol, 30, pp.131~137 (2016)
39. Boucle S, "Toward elimination of hepatitis B virus using novel drugs, approaches, and combined modalities", Clin Liver Dis, 20, pp.737~749 (2016)
40. Zhang H, "Safety, pharmacokinetics and anti-viral efficacy of novel core protein allosteric modifier GLS4 in patients with chronic hepatitis B : interim results from a 48 weeks phase 2a study", Hepatology, 68, pp.1454A~1455A (2018)
41. Yuen MF, "Antiviral activity, safety, and pharmacokinetics of capsid assembly modulator NVR 3-778 in patients with chronic HBV infection", Gastroenterology, 156, pp.1392~1403 (2019)
42. Eley T, "Single dose safety, tolerability, and pharmacokinetics of AB-423in healthy volunteers from the ongoing single and multiple ascending dose study AB-423-001", Hepatology, 66, pp.490A~490A (2017)
43. Kakuda TN, "JNJ-64530440, a novel capsid assembly modulator:single- and multiple-ascending dose safety, tolerability and pharmacokinetics in healthy volunteers", J Hepatol, 70(1), pp.469~ (2019)
44. Zoulim F, "Safety, pharmacokinetics and antiviral activity of a novel hepatitis B virus(HBV)capsid assembly modulator, JNJ-56136379, in patients with chronic hepatitis B(CHB)", Hepatology, 68, pp.47A~48A (2018)
45. Ma XL, "Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients", J Hepatol, 70, pp.e130~ (2019)
46. Yuen MF, "RO7049389, a core protein allosteric modulator, demonstrates robust decline in HBV DNA and HBV RNA in chronic HBV infected patients", J Hepatol, 70, pp.e491~ (2019)
47. Brezillon N, "Antiviral activity of Bay 41-4109 on hepatitis B virus in humanized Alb-uPA", SCID mice, 2011, pp.6, e25096~
48. Kalkeri R, "HBV core promoter inhibition by tubulin polymerization inhibitor(SRI-32007)", Adv Virol, 2020, pp.8844061~ (2020)
49. Kang JA, "Ciclopirox inhibits Hepatitis B Virus secretion by blocking capsid assembly", Nat Commun, 10, pp.2184~ (2019)
50. Lai CL, "Phase IIb multicentred randomised trial of besifovir(LB80380)versus entecavir in Asian patients with chronic hepatitis B", Gut, 63, pp.996~1004 (2014)
51. Ahn SH, "Efficacy and safety of besifovir dipivoxil maleate compared with tenofovir disoproxil fumarate in treatment of chronic hepatitis B virus infection", Clin Gastroenterol Hepatol, 17, pp.1850~1859 (2019)
52. Zhang H, "Randomised clinical trial : safety, efficacy and pharmacokinetics of HS-10234 versus tenofovir for the treatment of chronic hepatitis B infection", Aliment Pharmacol Ther, 53, pp.243~252 (2021)
53. Zhang P, "In vitro mitochondrial toxicity of metacavir, a new nucleoside reverse transcriptase inhibitor for treatment of hepatitis B virus", Antimicrob Agents Chemother, 54, pp.4887~4892 (2010)
54. Kristie Bloom, "Gene Therapy for Chronic HBV—Can We Eliminate cccDNA?", Genes, 9(4), pp.207~ (2018), MDPI AG[DOI]
55. Cong L, "Multiplex genome engineering using CRISPR", Cas systems, 2013, pp.339, 819~823
56. Cradick TJ, "Zincfinger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs", Mol Ther, 18, pp.947~954 (2010)
57. Bloom K, "Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases", Mol Ther, 21, pp.1889~1897 (2013)
58. Hsu PD, "Development and applications of CRISPR-Cas9 for genome engineering", Cell, 157, pp.1262~1278 (2014)
59. Seeger C, "Complete spectrum of CRISPR", Cas9-induced mutations on HBV cccDNA, 2016, pp.24, 1258~1266
60. Ramanan V, "CRISPR", Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus, 2015, pp.5, 10833~
61. Li H, "Removal of integrated hepatitis B virus DNA using CRISPR-Cas9", Front Cell Infect Microbiol, 7, pp.91~ (2017)
62. Karimova M, "CRISPR", Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X, 2015, pp.5, 13734~
63. Gilmore S, "Antiviral activity of GS-5801, a liver-targeted prodrug of a lysine demethylase 5 inhibitor, in a hepatitis B virus primary human hepatocyte infection model", J Hepatol, 66, pp.S690~S691 (2017)
64. "Characterization of a KDM5small molecule inhibitor with antiviral activity in rodent livers"[URL]
65. Hayakawa M, "Development of a novel anti-hepatitis B virus agent via Sp1", Sci Rep, 10, pp.47~ (2020)
66. Cheng ST, "Dicoumarol, an NQO1 inhibitor, blocks cccDNA transcription by promoting degradation of HBx", J Hepatol, 74, pp.522~534 (2021)
67. Belloni L, "IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome", J Clin Invest, 122, pp.529~537 (2012)
68. Vaillant A, "Nucleic acid polymers : broad spectrum antiviral activity, antiviral mechanisms and optimization for the treatment of hepatitis B and hepatitis D infection", Antiviral Res, 133, pp.32~40 (2016)
69. Bazinet M, "Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection naïve to nucleos(t)ide therapy", Gastroenterology, 158, pp.2180~2194 (2020)
70. Birmingham A, "3’ UTR seed matches, but not overall identity, are associated with RNAi off-targets", Nat Methods, 3, pp.199~204 (2006)
71. Yuen MF, "RNA interference therapy with ARC-520 results in prolonged hepatitis B surface antigen response in patients with chronic hepatitis B infection", Hepatology, 72, pp.19~31 (2020)
72. Gane E, "Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen supression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment", J Hepatol, 73, pp.S20~ (2019)
73. Yuen MF, "Results after 12 weeks treatment of multiple doses of GSK3389404in chronic hepatitis B subjects on stable nucleos(t)ide therapy in a phase 2a double-blind, placebo-controlled study", Hepatology, 70, pp.433A~ (2019)
74. Bertoletti A, "Adaptive immunity in HBV infection", J Hepatol, 64(1), pp.71~83 (2016)
75. Antonio Bertoletti, "Immunotherapy for Chronic Hepatitis B Virus Infection", Gut and Liver, 12(5), pp.497~507 (2018), 거트앤리버 소화기연관학회협의회
76. Ye B, "T-cell exhaustion in chronic hepatitis B infection : current knowledge and clinical significance", Cell Death Dis, 6, pp.e1694~ (2015)
77. Schnare M, "Toll-like receptors : sentinels of host defence against bacterial infection", Int Arch Allergy Immunol, 139, pp.75~85 (2006)
78. Janssen HLA, "Safety, efficacy and pharmacodynamics of vesatolimod(GS-9620)in virally suppressed patients with chronic hepatitis B", J Hepatol, 68, pp.431~440 (2018)
79. Daffis S, "Toll-like receptor 8 agonist GS-9688 induces sustained efficacy in the woodchuck model of chronic hepatitis B", Hepatology, 73, pp.53~67 (2021)
80. Gane E, "Efficacy and safety of 24 weeks treatment with oral TLR8 agonist, selgantolimod, in virally-suppressed adult patients with chronic hepatitis B : a phase 2 study", J Hepatol, 73, pp.S52~ (2020)
81. Sato S, "The RNA Sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus", Immunity, 42, pp.123~132 (2015)
82. Yuen RMF, "Ascending dose cohort study of inarigivir-a novel RIG I agonist in chronic HBV patients : final results of the ACHIEVE trial", J Hepatol, 70, pp.E47~E48 (2019)
83. Agarwal K, "Liver toxicity in the phase 2 catalyst 206 trial of inarigivir 400 mg daily added to a nucleoside in HBV eAg negative patients", J Hepatol, 73, pp.S125~ (2020)
84. Gane E, "Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B : a pilot study", J Hepatol, 71, pp.900~907 (2019)
85. Raziorrouh B, "The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus-specific CD8+ T-cell function", Hepatology, 52, pp.1934~1947 (2010)
86. Schurich A, "Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection", Hepatology, 53, pp.1494~1503 (2011)
87. Rollier C, "Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein", Gastroenterology, 116, pp.658~665 (1999)
88. Pol S, "Efficacy and limitations of a specific immunotherapy in chronic hepatitis B", J Hepatol, 34, pp.917~921 (2001)
89. Vandepapelière P, "Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy : a randomized, controlled study of co-administration of HBsAg", AS02 candidate vaccine and lamivudine, 2007, pp.25, 8585~8597
90. Godon O, "Immunological and antiviral responses after therapeutic DNA immunization in chronic hepatitis B patients efficiently treated by analogues", Mol Ther, 22, pp.675~684 (2014)
91. Fontaine H, "Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B : a randomised trial--ANRS HB02 VAC-ADN", Gut, 64, pp.139~147 (2015)
92. Obeng-Adjei N, "DNA vaccine cocktail expressing genotype A and C HBV surface and consensus core antigens generates robust cytotoxic and antibody responses in mice and Rhesus macaques", Cancer Gene Ther, 20, pp.652~662 (2013)
93. Yoon SK, "Safety and immunogenicity of therapeutic DNA vaccine with antiviral drug in chronic HBV patients and its immunogenicity in mice", Liver Int, 35, pp.805~815 (2015)
94. Gaggar A, "Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects : a randomized study", Vaccine, 32, pp.4925~4931 (2014)
95. Martin P, "TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBVpersistent mice", Gut, 64, pp.1961~1971 (2015)
96. Spyrou E, "Hepatitis B : current status of therapy and future therapies", Gastroenterol Clin North Am, 49, pp.215~238 (2020)
97. Gehring AJ, "Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines", J Hepatol, 55, pp.103~110 (2011)
98. Krebs K, "T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice", Gastroenterology, 145, pp.456~465 (2013)
99. Marcellin P, "Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B", N Engl J Med, 351, pp.1206~1217 (2004)
100. Lau GK, "Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B", N Engl J Med, 352, pp.2682~2695 (2005)
101. Janssen HL, "Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B : a randomised trial", Lancet, 365, pp.123~129 (2005)
102. Marcellin P, "Combination of tenofovir disoproxil fumarate and peginterferon α-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B", Gastroenterology, 150, pp.134~144 (2016)
103. Lee JH, "Entecavir plus pegylated interferon and sequential hepatitis B virus vaccination increases hepatitis B surface antigen seroclearance : a randomized controlled proof-of-concept study", Clin Infect Dis, 73, pp.e3308~e3316 (2021)
104. Peng D, "The clinical efficacy and adverse effects of entecavir plus thymosin alpha-1combination therapy versus entecavir monotherapy in HBV-related cirrhosis : a systematic review and meta-analysis", BMC Gastroenterol, 20, pp.348~ (2020)
105. Yuen MF, "Hepatitis B virus(HBV)surface antigen(HBsAg)inhibition with is 505358 in chronic hepatitis B(CHB)patients on stable nucleos(t)ide analogue(NA)-naïve CHB patients : phase 2a, randomized, double-blind, placebo-controlled study", J Hepatol, 73, pp.S49~S50 (2020)
106. Nassal M, "HBV cccDNA : viral persistence reservoir and key obstacle for a cure of chronic hepatitis B", Gut, 64, pp.1972~1984 (2015)
107. Lok AS, "Hepatitis B cure : from discovery to regulatory approval", J Hepatol, 67, pp.847~861 (2017)

관련 논문AI추천